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 Increasing intake of healthy or functional foods is the promising way to 
prevent noncommunicable diseases especially cardiovascular diseases (CVDs) which 
have been the number one cause of death in globe. Soybean (Glycine max) has been 
supported by significant scientific evidence particularly on the risk reduction of CVDs. 
With the aim of seeking a competitive functional soybean ingredient, a small black 
soybean cultivar with a green embryo commonly called Yak-Kong (YK) in Korea was 
chosen based on its physical characteristics and historical background and was 
evaluated its phenolics and their metabolites with a focus on prevention of CVDs. 
 First, antioxidant activities and phenolics of YK were analyzed. In comparison 
to common yellow and black soybean cultivars, YK contained significantly higher 
concentrations of antioxidants, particularly in its seed coat. A comprehensive phenolic 
composition analysis revealed that proanthocyanidins and isoflavones were the major 
phenolic groups in YK.    
 Potential effect of proanthocyanidins and isoflavones on prevention of CVDs 
was further evaluated with their prospective metabolites using a monocyte-endothelial 
cell adhesion in vitro assay. The present study found that 5-(3’,4’-dihydroxyphenyl)-γ-
 valerolactone (DHPV), one of the previously reported major human microbial 
metabolites of proanthocyanidins, strongly attenuated adhesion of THP-1 monocytes 
to tumor necrosis factor (TNF)-α-stimulated human umbilical vein endothelial cells 
(HUVECs). DHPV downregulated TNF-α-stimulated expressions of vascular cell 
adhesion molecule-1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1) and 
activation of nuclear factor-κB (NF-κB), which all are associated with atherosclerosis.
 Additionally, several hydroxylated metabolites of isoflavones in addition to 
their precursors were target-analyzed in the plasma of rat fed with YK embryo extract. 
7,8,4’-trihydroxyisoflavone (7,8,4’-THI), a hydroxylated daidzein metabolite, was 
exclusively detected with the highest amount (average 5.1 μM) and average 574.3 ± 
112.8 area under the curve within 240 min. In contrast to daidzein and daidzin, 7,8,4’-
THI significantly prevented adhesion of THP-1 monocytes to TNF-α-stimulated 
HUVECs via downregulating expressions of VCAM-1, MCP-1 and phosphorylation 
of I Kappa B Kinase (IKK) in NF-B signaling pathway. 
 In sum, YK has promising potential for further development as a functional 
food source targeted at atherosclerosis prevention. 
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CHAPTER 1 
INTRODUCTION 
Cardiovascular diseases and healthy diet 
 According to the World Health Organization (WHO, 2014), more than 50% of 
global deaths are due to noncommunicable diseases (NCDs) also known as chronic 
diseases that can be preventable. The number one cause of NCD deaths has been 
cardiovascular diseases (CVDs). CVDs killed 17.5 million people in 2012, 
representing more than 45% of NCD deaths (WHO, 2014). Among different types of 
CVDs such as coronary heart disease (CHD), cerebrovascular disease (CBD), 
hypertension, and peripheral arterial disease, CHD has been the number one cause of 
death for both men and women globally (WHO, 2011). It has been reported that the 
underlying process of CVDs, especially CHD and CBD, is atherosclerosis, a complex 
pathological process that develops plaques over time in walls of blood vessels (WHO, 
2011). The most important factors contributing to the development of atherosclerosis 
are unhealthy diets (rich in salt, fat, and calories), tobacco use, physical inactivity, and 
harmful use of alcohol (WHO, 2011). Therefore, the main prevention strategy for 
atherosclerosis is lifestyle changes such as increasing intake of fruits, vegetables, and 
fish but decreasing salt, saturated fat, and trans-fat cholesterol in diets (WHO, 2011). 
Application of healthy diets and functional foods is a promising way to prevent NCDs, 
including CVDs and atherosclerosis.  
 
Atherosclerosis and antioxidative phenolics 
 Previously, it has been elucidated that atherosclerosis is not a simple lipid-
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storage disease, but a chronic inflammatory disease (Ross, 1999). Atherosclerosis 
starts once vascular endothelial cells are dysfunctional (Plutzky, Viberti & Haffner, 
2002). Several risk factors including smoking, intake of diets rich in saturated fat, salt 
and calorie, and other stress inducers can damage innate functions of vascular 
endothelial cells such as regulation of endothelium permeability and adhesiveness of 
leukocytes to the arterial wall (WHO, 2011; Libby, 2006). Some other disease 
conditions such as obesity, insulin resistance, hyperglycemia, hypertension, and 
infection can also cause endothelial dysfunction (Libby, Ridker & Maseri, 2002). 
These risk factors can potentially induce oxidation of low-density lipoprotein and 
elevation of reactive oxygen species (ROS) levels or reduce antioxidants/antioxidant 
synthase (Libby, 2006; Plutzky et al., 2002). ROSs such as O2
∙-
, 
1
O2, HO
∙
, NO
∙
, 
ONOO
-
, HOCL, RO(O)
∙
, and LO(O)
∙
 are either radicals or reactive non-radical 
compounds that are capable of oxidizing biomolecules (Prior, Wu & Schaich, 2005). 
Antioxidants can scavenge ROSs and free radicals by donating electrons or hydrogens 
(Halliwell & Gutteridge, 1995). Numerous studies support that antioxidants and 
polyphenols from fruits and vegetables can potentially lower the risk of mortality from 
CVDs (Wang et al., 2014). 
 Potential health benefits of naturally occurring antioxidants and polyphenols 
have been studied extensively in the past two decades. Their structures have been 
characterized to have at least one aromatic ring with hydroxyl groups (El Gharras, 
2009). Polyphenols can be divided into four different classes: phenolic acids, 
flavonoids, stilbenes, and lignans (El Gharras, 2009). Flavonoids are the largest class 
of polyphenols that share a common structure consisting of two aromatic rings bound 
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together with three carbon atoms, forming an oxygenated heterocycle (C ring) 
(RiceEvans, Miller & Paganga, 1996). It has been found that the antioxidant activity 
of flavonoids such as delocalization of unpaired electrons is derived from their ortho-
dihydroxy structure in the B ring, 2 & 3 double bond conjugated with a 4-oxo group in 
the C ring, and 3- & 5-OH groups with 4-oxo group in A and C rings (RiceEvans et 
al., 1996). Based on the type of heterocycle function (Figure 1.1), flavonoids can be 
further divided into six subclasses: flavones, flavanones, flavonols, flavanonols, 
flavan-3-ols, anthocyanidins, and isoflavonoids (El Gharras, 2009).  
 
Figure 1.1. Structures of flavonoids. 
 
 4 
 
Soybean as a CHD preventive food ingredient  
 Soybean (Glycine max) is a popular food source for health-conscious 
consumers. It has numerous health benefits (United Soybean Board, 2014). High 
consumption of soy protein has been associated with reduced incidence of CHD 
(Anderson & Bush, 2011). In contrast to other members of the Leguminosaea family 
including Phaseolus (pinto bean, kidney bean), Lens (lentil), and Vigna (blackeyed 
pea, mung bean), only Glycine max (soybean) protein as an ingredient has been 
granted a health claim by the U.S. Food and Drug Administration (FDA) (1999). FDA 
(1999) has approved the health claim that consumption of 25 grams soy protein a day 
as part of a diet low in saturated fat and cholesterol may reduce the risk of CHD. In 
addition to soy protein, other soybean phytochemicals such as isoflavones have been 
widely studied for their potential to lower the risks of chronic diseases through their 
antioxidant, anti-inflammatory, and other bioactive properties (Boye & Ribereau, 
2011; O’Bryan et al., 2014). 
 
Phenolics of black soybean  
 Several studies have reported that black soybean has a higher antioxidant 
capacity than yellow soybean (Takahashi, Ohmori, Kiyose, Momiyama, Ohsuzu & 
Kondo, 2005; Xu et al., 2008), and black soybean extract may prevent the 
development of chronic diseases including diabetes, obesity (Kanamoto et al., 2011) 
and thrombotic disease (Kim et al., 2011). Unlike yellow soybean, black soybean 
contains additional phytochemicals besides isoflavones, such as anthocyanins and 
proanthocyanidins in its seed coat (Todd & Vodkin, 1993).  
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CHAPTER 2 
COMPREHENSIVE PHENOLIC COMPOSITION ANALYSIS AND 
EVALUATION OF YAK-KONG SOYBEAN (GLYCINE MAX) FOR THE 
PREVENTION OF ATHEROSCLEROSIS  
Abstract 
 With the aim of seeking a competitive soybean ingredient for prevention of 
cardiovascular diseases (CVDs), a small black soybean cultivar with a green embryo 
(Glycine max) commonly called Yak-Kong (YK) in Korea was chosen among the 
many black soybean cultivars based on its physical characteristics and historical 
background. We evaluated the potential of YK as a functional food by comparing its 
total antioxidant activity to the common yellow soybean (YS) and black soybean (BS) 
cultivars. In comparison to YS and BS, YK contains significantly higher 
concentrations of phenolics, particularly in its seed coat. In addition, we conducted a 
comprehensive analysis of the phenolic compounds present in YK and evaluated them 
with a focus on prevention of CVDs. It revealed that proanthocyanidins and 
isoflavonoids are the major phenolic groups in each seed coat and embryo of YK 
respectively. In addition, YK was a good source of flavan-3-ols, cyanidin-3-glucoside, 
protocatechuic acid, coumestrol and phloridzin. We demonstrated that both YK seed 
coat and embryo are important potential sources of CVD-preventive phenolics.  
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Introduction 
 Among the few health claims for functional foods supported by significant 
scientific evidence, the U.S. Food and Drug Administration (FDA) (1999) has 
approved the claim of coronary heart disease (CHD) risk reduction for protein present 
in soybean (Glycine max). Additionally, a meta-analysis conducted by Zhan & Ho, 
2005 demonstrated that consumption of soy protein together with a higher dosage of 
isoflavones exerts stronger effects on CHD risk reduction than soy protein intake 
alone. Proanthocyanidins and anthocyanins have also shown potential health benefits 
for risk reduction of cardiovascular diseases (CVDs) including CHD (Hooper et al., 
2008; McCullough, Peterson, Patel, Jacques, Shah & Dwyer, 2012; Mink et al., 2007). 
A meta-analysis of 133 randomized controlled trials showed that proanthocyanidins- 
and flavan-3-ol-rich foods such as chocolate, cocoa and black tea are linked to the 
reduction of several CVDs risk factors (Hooper et al., 2008). Additionally, several 
large prospective cohort studies have shown that anthocyanin-rich foods have a 
positive effect on CVDs risk reduction (McCullough et al., 2012; Mink et al., 2007). 
These findings were the basis for our hypothesis that black soybean is more effective 
functional soybean for CVDs prevention than yellow soybean.   
 Numerous soybean varieties are found in Korea, China and Japan, as soybean 
originated from East Asia and has been cultivated since 7050-3050 BC (Lee, 
Crawford, Liu, Sasaki & Chen, 2011). Historical records show that black soybean was 
particularly favored as a herbal medicine (Xu & Chang, 2008). The various black 
soybean cultivars can be distinguished by their size and embryo color. In Korea, a 
small black soybean with green embryo commonly called Yak-Kong (YK) (Glycine 
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max) is being recognized for its medicinal properties, and particularly for improving 
blood circulation and kidney health. People have consumed Yak-Kong in soup and 
fermented alcohol to treat nervous disorders and as a detoxification agent against food 
poison. However, there is a lack of scientific research to support these claims. In this 
study, we evaluated the potential of YK as a functional food by comparing its total 
antioxidant activity to the common yellow soybean (YS) and black soybean (BS) 
cultivars. In addition, we conducted a comprehensive analysis of the phenolic 
compounds present in YK and evaluated them with a focus on prevention of CVDs. 
 
Materials and methods 
 Chemicals and Reagents. Food-grade ethanol (95%) was purchased from 
Daehan Ethanol Life (Seoul, Republic of Korea). Liquid chromatography-grade 
solvents including acetone and acetonitrile were purchased from EMD Millipore 
Chemicals (Billerica, MA, USA), while glacial acetic acid, formic acid and phosphoric 
acid were obtained from Anachemia (Quebec, Canada). Phenolic standards were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were 
purchased from Merck KGaA (Darmstad, Germany). 
 Soybean Materials. Three different soybeans (Glycine max) were used in this 
study. Standardized YK soybean (Registration number: 01-0003-2013-3) was 
provided by the Rural Development Administration, Republic of Korea. The 
remaining two (YS and BS) were purchased from local suppliers in Danyang and 
Boeun, Republic of Korea in 2016.  
 Preparations of Soybeans. The physical characteristics of the three soybeans 
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are presented in Figure 2.1. Soybean size differences were characterized by the 
numbers of seeds on a per-weight basis. Weight proportions for the seed coats and 
embryos in whole soybean were also calculated. Soybean sample preparations and the 
extraction procedure are shown in Figure 2.2A & B. Briefly, whole ground soybeans 
were extracted with 50% ethanol at 25 °C for 3 h. The peeled seed coats were 
extracted with 50% ethanol at 75 °C for 1.5 h. The 3 mm cut embryos were extracted 
with 70% ethanol at 75 °C for 3 h. YK seed coat and embryo extracts were then 
freeze-dried as powders. 
 
 
 
 
Figure 2.1. Physical characteristics of the three soybean samples. 
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A. 
 
B. 
 
Figure 2.2. Soybean sample preparations (A) and extractions (B). 
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 Determination of Total Antioxidant Activity. Total antioxidant activity was 
measured using the method developed by Blois (1958) with some modifications. 
Briefly, the samples were mixed with 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical 
solution and incubated in 96-well plates. The absorbance was measured at 517 nm, 
and the results were expressed as milligrams of ascorbic acid equivalent (ACE) per 
gram of whole soybean or soybean parts. 
 Determination of Total Phenolic Content. Total phenolic content was 
determined using the Folin-Ciocalteu (FC) assay (Singleton & Rossi, 1965) with some 
modifications. Briefly, the samples were mixed with FC phenol reagent, 7% Na2CO3 
and ddH2O in 96-well plates with an appropriate incubation time. The absorbance was 
compared against ddH2O at 750 nm, and the results were expressed as milligrams of 
gallic acid equivalents (GAE) per gram of whole soybean. 
 Determination of Total Flavonoid Content. Total flavonoid content was 
measured using the method initially proposed by Christ and Muller (1960) with some 
modifications. The samples were mixed with 5% NaNO2, 10% AlCl36H2O, 1 M 
NaOH and ddH2O in 96-well plates with an appropriate incubation time. The 
absorbance was read against ddH2O at 510 nm, and the results were expressed as 
milligrams of catechin equivalents (CE) per gram of whole soybean. 
 Determination of Total Anthocyanin Content. Total anthocyanin content 
was measured using the pH differential method (Lee, Durst & Wrolstad, 2005) with 
some modifications. In 96-well plates, 0.025 M KCl (pH 1.0) and 0.4 M CH3COONa 
(pH 4.5) were added to the samples with appropriate dilution factors. The absorbance 
was measured against ddH2O at 510 nm (λvis-max of Cyanidin-3-glucoside (C3G)) and 
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700 nm. The total anthocyanins (mg/g whole soybean) were calculated based on 
Lambert-Beer’s Law: (A x MW x DF x 1000)/(ε x 1). (A: Absorbance = (Aλvis-max – 
A700nm)pH1.0 – (Aλvis-max – A700nm)pH4.5, DF: Dilution factor, ε: C3G molar absorptivity 
coefficient = 26900 M
-1 
cm
-1
, MW: C3G molecular weight = 449.2) 
 Determination of Phenolic Composition.  
 Ultra-High Performance Liquid Chromatography-photodiode Array (UHPLC–
PDA) Analysis. Isoflavonoids were analyzed by reversed phase UHPLC using a 
Waters Acquity UPLC coupled to a PDA detector (Milford, MA, USA). The 
compounds were separated at 30°C on a Waters Acquity HSS Cyano column (2.1 mm 
x 50 mm, 1.8 µm) using a mobile phase consisting of 0.1% formic acid in water 
(solvent A) and 0.1% formic acid in acetonitrile (solvent B) mixed using the following 
gradient: 0–0.36 min, 10% B; 0.36–3.6 min, 10–30% B; 3.6–3.96 min, 30% B; 3.96–4 
min, 10% B; 4–6 min, 10% B, with a flow rate of 0.58 ml/min and an injection 
volume of 1 μl. Chromatographic data were acquired at 260 nm. Daidzein, glycitein 
and their derivatives were quantified using calibration curves prepared with a daidzein 
standard, while genistein and coumestrol were quantified using their corresponding 
standards.  
 HPLC–Fluorescence Analysis. Proanthocyanidins were analyzed by normal-
phase analytical HPLC with fluorescence detection as previously described by 
Dudonné et al (2014). The fluorescence was monitored at excitation and emission 
wavelengths of 230 and 321 nm respectively. Proanthocyanidins with degrees of 
polymerization (DP) from 1 to >10 were quantified using an external calibration curve 
of epicatechin, applying a correction factor according to their respective responses in 
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fluorescence.  
 UHPLC–Tandem Quadrupole Detector-Mass Spectrometer (TQD–MS) and 
UHPLC–Quadrupole Time of Flight (QToF–MS) Analyses. YK seed coat extract was 
further analyzed by reverse-phase UHPLC coupled to tandem mass spectrometry as 
previously published by Dudonné et al. (2014) using a Waters Acquity HSS T3 
column (2.1 x 150 mm, 1.8 μm), tracking specific transitions of A- and B-type dimers 
of procyanidins (577 > 289 and 575 > 289 respectively) through multiple reaction 
monitoring (MRM) mode. The presence of A-type dimers of procyanidins in YK seed 
coat extract was confirmed using UHPLC–QToF–MS. Briefly, the analysis was 
conducted on an Agilent 6560 instrument coupled to an LC 1290 Infinity II system 
(Santa Clara, CA, USA) with a Waters Acquity HSS T3 column (2.1 x 100 mm, 1.8 
μm). The elution was performed at 40 °C with a flow rate of 0.4 ml/min using a linear 
gradient for 30 min which changed from 98% A (0.1% formic acid in water) to 100% 
B (0.1% formic acid in acetonitrile). The QToF–MS instrument was operated with an 
electrospray ion source ESI–Agilent Jet Stream Technology in negative ionization 
mode. The MS scan data were collected at a rate of 1 spectra/s in the range of m/z 
100–1,000 in high resolution mode. A collision cell with nitrogen as collision gas and 
collision energy 0–40 eV was used. A-type procyanidin dimers were identified using 
MassHunter Qualitative Analysis B.06.00 with Service Pack 1 software and were 
confirmed with their exact molecular mass. 
 Anthocyanins were analyzed using a Waters Acquity UPLC H-Class system 
equipped with a quaternary pump system. A Supelco Titan C18 column (100 mm x 
2.1 mm id, 2.0 mm particle size) was used. The anthocyanins were separated with a 
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mobile phase that consisted of 10% acetic acid (eluent A) and acetonitrile (eluent B). 
The flow-rate was 0.4 ml/min and the gradient elution was 0–10 min, 5–35% B; 10–
10.10 min, 35–80% B; 10.10–11.00 min, isocratic 80% B; 11.0–11.10 min, 80–5% B. 
The MS analyses were carried out on a Waters Xevo TQD mass spectrometer 
equipped with a Z-spray electrospray interface. The analysis was performed in 
positive mode and the data was acquired through MRM, tracking transitions of 40 
glycosylated anthocyanins. The ionization source parameters were capillary voltage, 
2.50 kV; source temperature, 150 °C; cone gas flow rate, 50 l/h and desolvation gas 
flow rate, 800 l/h; desolvation temperature, 400 °C. Nitrogen (99% purity) and argon 
(99% purity) were used as nebulizing and collision gases, respectively. 
 UHPLC–Tandem Mass Spectrometer (MS/MS) Analysis. Phenolic acids and all 
other phenolics were analyzed by UHPLC–MS/MS using the same parameters as in 
the proanthocyanidin analysis. Data were acquired in negative ionization mode 
through MRM. All phenolic compounds were quantified as GAE. 
 Statistics. The results were expressed as means ± SD and compared using 
SPSS (Statistical Analysis System Institute, 2010). The significance between mean 
values was determined by Tukey’s Honest Significant Difference test at P < 0.05.  
 
Results  
 Comparison of Physical Characteristics, Total Antioxidant Activity and 
Total Phenolic Content between BS, YS and YK. Physical characteristics of the 
three soybean types are shown in Figure 2.1. YK was the smallest as it had more seeds 
per gram, with an average of 5, 8 and 18 seeds per gram were recorded for BS, YS and 
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YK, respectively. As seed size decreased, the proportion of seed coat in the whole 
soybean increased. The seed coat weight proportion averaged 8%, 9% and 12% for 
BS, YS and YK, respectively. 
 Analyses of the total antioxidant activity, total phenolics, total flavonoids and 
total anthocyanins between the three whole soybeans (Figure 2.3A-D) revealed that 
one gram of YK showed higher total antioxidant activity (4.44 ± 0.30 mg ACE), total 
phenolic content (6.14 ± 0.18 mg GAE), total flavonoid content (1.50 ± 0.07 mg CE) 
and total anthocyanin content (0.51 ± 0.01 mg C3G equivalent) than the other two 
soybean types (P < 0.05).  
 When seed coats and embryos of the three soybeans were isolated and 
compared for antioxidant activity (Figure 2.3E & F), both YK seed coat and embryo 
showed higher total antioxidant activity (P < 0.05). One gram of YK seed coat 
harbored 55.92 ± 1.64 mg ACE, which was approximately 30 times higher than for YS 
embryo (1.76 ± 0.41 mg ACE).  
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Figure 2.3. Comparison of antioxidant profiles among soybean cultivars. (A) Total 
antioxidant activity, (B) total phenolic content, (C) total flavonoid content and (D) 
total anthocyanin content in whole soybeans. (E) Total antioxidant activity in 
separated seed coats and (F) embryos. Data are expressed as means ± SD (n = 3). 
Different letters denote significant differences (P < 0.05); values bearing the same 
letters are not significantly different from each other. YK, Yak-Kong; BS, black 
soybean; YS, yellow soybean; ACE, ascorbic acid equivalents; GAE, gallic acid 
equivalents; CE, catechin equivalents; and C3G, cyanidin-3-glucose. 
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 Comprehensive Phenolic Composition of YK. Comprehensive phenolic 
composition analysis of the YK seed coat and embryo was conducted for 
isoflavonoids, proanthocyanidins, anthocyanins, phenolic acids and other phenolics 
(Figure 2.4).  
 
Figure 2.4. List of analyzed phenolics. 
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 Compounds with higher than the average 0.1 mg/100 g whole YK were 
selected and are shown in Table 2.1. YK seed coat contained 1867.05 ± 29.92 mg 
phenolics per 100 g, a value which was on average 8 times higher than for YK embryo 
(225.22 ± 1.91 mg/100 g). Phenolic content in whole YK (422.42 ± 5.2 mg/100 g) was 
calculated based on the % weight ratio of seed coat to embryo (12:88). Among the 
phenolic groups determined for whole YK, proanthocyanidin was the major group 
comprising more than 70% of the total phenolic composition. YK seed coat 
contributed more than 50% of the total phenolic composition for whole YK, however 
more than 90% of the isoflavonoids in whole YK was contained in the embryo.  
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Table 2.2. YK phenolic composition
a
 
Compounds 
Seed coat  Embryo  Whole
b
 
mg/100g %
c
  mg/100g %  mg/100g % 
% Distribution
d
 
(Seed coat: Embryo) 
Phenolics 1867.05 ± 29.92 100  225.22 ± 1.91 100  422.24 ± 5.23 100 53:47 
 Flavonoids 1814.88 ± 26.99 97.21  223.22 ± 2.05 99.11  414.21 ± 4.97 98.10 53:47 
  Total proanthocyanidins 1522.97 ± 21.77 81.57  133.83 ± 1.40 59.42  300.53 ± 3.81 71.17 61:39 
    Monomers 646.53 ± 12.91 34.63  12.23 ± 1.21 5.43  88.34 ± 1.74 20.92 88:12 
    Dimers 415.03 ± 2.52 22.23  ND
e -  49.80 ± 0.30 11.80 100:0 
    Trimers 176.23 ± 4.36 9.44  ND -  21.15 ± 0.52 5.01 100:0 
    Ttetramers 88.17 ± 0.64 4.72  ND -  10.58 ± 0.08 2.51 100:0 
    Pentamers 47.92 ± 2.79 2.57  ND -  5.75 ± 0.34 1.36 100:0 
    Hexamers 33.16 ± 2.71 1.78  ND -  3.98 ± 0.32 0.94 100:0 
    Heptamers 12.55 ± 1.66 0.67  ND -  1.51 ± 0.20 0.36 100:0 
    Octamers 7.93 ± 0.70 0.42  ND -  0.95 ± 0.08 0.23 100:0 
    Nonamers 7.25 ± 2.53 0.39  ND -  0.87 ± 0.30 0.21 100:0 
    Polymers (DP>10) 88.21 ± 1.72 4.72  121.61 ± 1.35 53.99  117.60 ± 0.98 27.85 9:91 
  Isoflavonoids 44.94 ± 1.34 2.41  76.55 ± 1.48 37.94  72.75 ± 1.27 19.09 7:93 
    Coumestrol ND -  8.91 ± 0.61 3.96  7.84 ± 0.54 1.86 0:100 
   Daidzein derivatives 21.58 ± 1.24 1.16  24.38 ± 0.54 10.82  24.04 ± 0.55 5.69 11:89 
    Daidzin 11.03 ± 0.01 0.59  14.50 ± 0.41 6.44  14.08 ± 0.36 3.33 9:91 
    Acetyl daidzin 0.52 ± 0.01 0.03  1.14 ± 0.01 0.51  1.07 ± 0.00 0.25 6:94 
    Malonyl daidzin 9.90 ± 1.22 0.53  8.50 ± 0.11 3.78  8.67 ± 0.20 2.05 14:86 
    Daidzein 0.12 ± 0.02 0.01  0.23 ± 0.02 0.10  0.22 ± 0.02 0.05 7:93 
   Genistein derivatives 9.18 ± 0.47 0.49  39.47 ± 0.68 17.53  35.84 ± 0.58 8.49 3:97 
    Genistin 2.08 ± 0.17 0.11  22.32 ± 0.47 9.91  19.89 ± 0.42 4.71 1:99 
    Acetyl genistin 0.54 ± 0.01 0.03  1.82 ± 0.01 0.81  1.67 ± 0.01 0.39 4:96 
    Malonyl genistin 6.32 ± 0.40 0.34  14.29 ± 0.22 6.34  13.33 ± 0.15 3.16 6:94 
    Gnistein 0.23 ± 0.02 0.01  1.04 ± 0.01 0.46  0.94 ± 0.01 0.22 3:97 
   Glycitein derivatives 14.19 ± 0.33 0.76  12.70 ± 0.51 5.64  12.88 ± 0.47 3.05 13:87 
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Table 2.1 (Continued) 
    Glycitin 5.07 ± 0.37 0.27  7.02 ± 0.43 3.12  6.79 ± 0.39 1.61 9:91 
    Acetyl glycitin` 0.49 ± 0.03 0.03  2.06 ± 0.34 0.91  1.87 ± 0.30 0.44 3:97 
    Malonyl glycitin 6.46 ± 0.11 0.35  3.26 ± 0.29 1.45  3.64 ± 0.24 0.86 21:79 
    Glycitein 2.16 ± 0.09 0.12  0.36 ± 0.00 0.16  0.58 ± 0.01 0.14 45:55 
  Flavan-3-ols 129.14 ± 3.92 6.92  2.65 ± 0.69 1.18  17.83 ± 1.06 4.22 87:13 
    Catechin 46.34 ± 1.60 2.48  0.37 ± 0.04 0.16  5.88 ± 0.16 1.39 95:5 
    Epicatechin 82.80 ± 3.68 4.43  2.28 ± 0.73 1.01  11.94 ± 1.00 2.83 83:17 
  Flavonols 83.46 ± 4.86 4.47  0.62 ± 0.14 0.28  10.57 ± 0.47 2.50 95:5 
    Quercetin 3.44 ± 0.75 0.18  0.18 ± 0.12 0.08  0.57 ± 0.06 0.14 72:28 
    Quercetin-3-arabinoside 0.25 ± 0.04 0.01  ND -  0.03 ± 0.00 0.01 100:0 
    Quercetin-diglucoside 3.44 ± 0.75 0.18  0.18 ± 0.12 0.08  0.57 ± 0.06 0.14 72:28 
    Quercetin-galactoside 22.01 ± 1.12 1.18  0.04 ± 0.03 0.02  2.68 ± 0.12 0.63 99:1 
    Quercetin-glucoside 28.40 ± 1.65 1.52  0.14 ± 0.06 0.06  3.53 ± 0.17 0.84 97:3 
    Quercetin-3-rutinoside  25.86 ± 2.62 1.38  0.08 ± 0.07 0.04  3.17 ± 0.37 0.75 98:2 
  Total anthocyanins 32.17 ± 1.88 1.72  0.65 ± 0.01 0.29  4.43 ± 0.22 1.05 87:13 
    Cyanidin 3-glucoside 30.65 ± 1.85 1.64  0.61 ± 0.01 0.27  4.21 ± 0.21 1.00 87:13 
  Chalconoids 
    Phloridzin 
2.20 ± 0.70 0.12  ND -  0.26 ± 0.08 0.06 100:0 
 Phenolic acids 52.17 ± 3.21 2.79  2.01 ± 0.17 0.89  8.03 ± 0.26 1.90 78:22 
    p-Coumaric acid 0.42 ± 0.27 0.02  1.12 ± 0.15 0.50  1.04 ± 0.15 0.25 5:95 
    4-Hydroxybenzoic acid 0.55 ± 0.04 0.03  0.19 ± 0.05 0.08  0.23 ± 0.04 0.05 29:71 
    Protocatechuic acid 50.22 ± 3.16 2.69  0.57 ± 0.04 0.25  6.52 ± 0.41 1.55 92:8 
a 
Data are expressed as means ± SD (n = 3) on a dry weight basis.
 b 
Phenolics in whole YK [= (0.12 x seed coat value) + (0.88 x 
embryo value)]. 
c 
% Phenolic composition [= 100 x (each value/total phenolics measured in each part)]. 
d
 % Phenolic distribution 
ratio of seed coat to embryo in whole YK [= 100 x (0.12 x seed coat value)/(whole value):100 x (0.88 x embryo value)/(whole 
value)]. 
e 
ND, not detectable.  
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 Proanthocyanidins of various DP were measured in YK. YK seed coat 
contained significantly higher concentrations of proanthocyanidins (1522.97 ± 21.77 
mg/100 g) (P < 0.05) with various DP compared to YK embryo (133.83 ± 1.40 
mg/100 g) which only comprised monomers and polymers (DP ≥ 10). The 
proanthocyanidin dimer types were further characterized by UHPLC–TQD–MS 
(Figure 2.5A). Several peaks were exclusively detected at the molecular mass of A-
type procyanidin dimers (MW: 576.52 g/mol) rather than at the molecular mass of B-
type procyanidin dimers (MW: 578.52 g/mol). The presence of A-type procyanidins 
was validated using UHPLC–QToF–MS (Figure 2.5B) with a mass obtained from the 
system at 0.3 ppm error of 575.5044 (M-H) (C30H24O12) and a 93% isotope match.  
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A. 
 
B. 
 
Figure 2.5. Identification of A type procyanidin dimers in YK seed coat extract by (A) UHPLC–TQD–MS and (B) UHPLC-QToF-
MS. Specific A-type procyanidin dimers were detected by TQD-MS tracking MRM transitions of A- and B-type procyanidin 
dimers (577 > 289 and 575 > 289 respectively) (A), and confirmed by QToF–MS (B).
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 Significant concentrations of isoflavonoids were found in whole YK (72.75 ± 
1.27 mg/100 g). Daidzein and genistein derivatives including their acetyl, malonyl and 
aglycon forms were the major isoflavones present at 1.16% and 17.53% of the total 
phenolic composition in YK seed coat and embryo, respectively. Among the 
aglycones, a high concentration of glycitein was found in YK seed coat (2.16 ± 0.09 
mg/100 g). Except glycitein, more than 75% of all other YK isoflavones were located 
in the embryo. In particular, the high concentration of coumestrol in whole YK (7.84 ± 
0.54 mg/100 g) was exclusively derived from its embryo.  
 Less than 10 % of phenolics in whole YK were comprised of flavan-3-ols, 
flavonols, anthocyanins and phenolic acids. Cyanidin-3-glucosid and protocatechuic 
acid were the main anthocyanins and phenolic acids, respectively. More than 70% of 
these four phenolic subclasses in whole YK were derived from its seed coat. YK seed 
coat also exclusively contained phloridzin (2.20 ± 0.70 mg/100 g).  
 
Discussion 
 In the present study, we compared antioxidant profiles among the three 
soybeans and conducted a comprehensive analysis of the composition of the phenolic 
compounds present in YK. We found that YK contains higher concentrations of total 
phenolics including flavonoids and anthocyanins (P < 0.05) and exhibits significantly 
higher antioxidant activity than YS and BS. Phenolic compound profiling of YK as 
analyzed by UHPLC–MS/MS showed that proanthocyanidins and isoflavonoids were 
the major phenolic groups, representing more than 90% of the total phenolic 
composition. YK seed coat contained particularly higher concentrations of phenolic 
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compounds than the embryo. 
 A previous study reported that black soybean contains phenolics such as 
protocatechuic acid that have not been identified in other soybean types (Kanamoto et 
al., 2011). We therefore conducted additional phenolic composition analyses for YK 
and found several new phenolics, most of which were in the seed coat. YK seed coat 
harbored significant concentrations of phloridzin. Phloridzin has been predominantly 
found in apple and is used as a pharmaceutical for the treatment of diabetes mellitus, 
as it functions as an inhibitor of the sodium-glucose transporter (Ehrenkranz, Lewis, 
Kahn & Roth, 2005). Phloridzin was also found to exist in strawberry (Hilt et al., 
2003), however this marks the first report of its presence in soybean. In addition to 
phloridzin, YK seed coat was found to contain several isomers of A-type procyanidins 
potentially linkage between catechin or epicatechin units (Sarnoski, Johnson, Reed, 
Tanko & O’Keefe, 2012). In contrast to an abundance of B-type proanthocyanidin-
containing foods such as cocoa, grape seed, red wine and berries, only a small number 
of foods are known to contain A-type proanthocyanidins, including cranberry, plum, 
cinnamon and peanut skin (Bhagwat & Haytowitz, 2015). This marks the first report 
of A-type proanthocyanidins found in soybean (Glycine max), a completely different 
genus to peanut (Arachis hypogaea), which is also in the Leguminosae family.  
 It was reported that A-type proanthocyanidins can be absorbed in their native 
forms with higher efficiency than B-type proanthocyanidins (Appeldoorn, Vincken, 
Gruppen & Hollman, 2009). In addition, more than 50% of proanthocyanidins in YK 
were of low DP (DP ≤3), which are more easily absorbed than highly polymerized 
proanthocyanidins (Deprez, Mila, Huneau, Tome & Scalbert, 2001). This is in contrast 
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to most known foods containing proanthocyanidins as polymers (DP ≥ 10) (Bhagwat 
et al., 2015). When the present results were compared to those in the U.S. Department 
of Agriculture (USDA) database, which used the same proanthocyanidin quantifying 
method as our study, whole YK was found to contain higher concentrations of 
proanthocyanidin dimers than other legumes and nuts including black-eyed pea, 
peanut and berries, such as cranberry (Bhagwat et al., 2015). YK seed coat as a food 
ingredient also contained higher concentrations of proanthocyanidin dimers than other 
food ingredients including grape skin, dried cocoa powder and cinnamon powder 
(Bhagwat et al., 2015). Taken together, these results indicate that YK seed coat is an 
excellent source of bioavailable proanthocyanidins.  
 YK embryo is a good source of isoflavonoids, particularly coumestrol. The 
total quantity of isoflavones in YK was comparable to various other soybeans 
common in different countries (Kim, Ro, Kim, Kim & Chung, 2012; Xu et al., 2008). 
In the case of coumestrol, it is known that only a few foods contain considerable 
amounts, such as red clover, clover sprouts and Kala Chana (Bhagwat, Haytowitz & 
Holden, 2008). In contrast to the USDA database which reports small concentrations 
of coumestrol in beans and bean sprouts (Bhagwat et al., 2008), significant amounts of 
coumestrol were found in YK. Coumestrol has been shown to have higher low density 
lipoprotein-antioxidant activity compared to genistein and daidzein (Lee et al., 2006), 
however there has been no direct evidence yet whether it has CVDs preventive 
bioactivity.  
 YK seed coat was found to have a very similar phenolic composition to 
pycnogenol, which is the dietary supplement derived from pine bark and standardized 
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to contain 65–75% proanthocyanidin and other phenolics such as (epi)catechins and 
phenolic acids, and are alleged to prevent or treat cardiovascular disorders (Kim, Kim, 
Kang, Sung & Kang, 2010). And as mentioned earlier, meta-analyses conducted by 
other research groups have shown strong correlations between CVDs prevention and 
the consumption of proanthocyanidin- or anthocyanin-rich foods and soy protein 
together with isoflavones (Zhan et al., 2005; Hooper et al., 2008; Mink et al., 2007; 
McCullough et al., 2012). Several randomized controlled trials have also demonstrated 
that the consumption of cranberry products, which are rich in A type 
proanthocyanidins may provide cardioprotective benefits such as improvement of lipid 
profile and blood pressure and the reduction of lipid peroxidation biomarkers 
expression and cell adhesion molecules (Blumberg et al., 2016). In addition, a number 
of in vivo studies have shown that phloridzin may provide protective effects against 
diabetic cardiomyopathy or atherosclerosis triggered by a high glucose diet (Azuma et 
al., 2006; Cai et al., 2013) and increase the absorption efficacy of isoflavone 
(Andlauer, Kolb & Furst, 2004). Taken together, the present results suggest that YK 
could be an effective functional soybean ingredient for atherosclerosis prevention. 
 
Conclusion 
 Soybean appears to be a complex food material harboring various types of 
phenolic compounds, not only limited to isoflavones. Depending on the soybean 
cultivar and cultivation conditions, harvest time and processing methods, the 
phytochemical profiles of soybean are likely to be varied. Therefore, comprehensive 
phenolic composition analyses are necessary to characterize the different soybeans, 
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particularly their seed coat. YK was found to be a competitive functional soybean in 
regards to higher concentrations of antioxidants than YS and BS and phenolics that are 
potentially beneficial for atherosclerosis prevention. YK was a good source of not only 
isoflavonoids, particularly coumestrol in its embryo but also bioavailable 
proanthocyanidins (DP ≤ 3) with A-type dimers, flavan-3-ols, cyanidin-3-glucoside, 
protocatechuic acid and phloridzin in its seed coat. We demonstrated that both YK 
seed coat and embryo are important potential sources of CVDs-preventive phenolics. 
The higher consumption of YK as a whole may therefore potentially impart numerous 
health benefits including atherosclerosis prevention. 
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CHAPTER 3 
5-(3’, 4’ DIHYDROXYPHENYL-γ-VALEROLACTONE), A MAJOR MICROBIAL 
METABOLITE OF PROCYANIDIN, ATTENUATES MONOCYTE-
ENDOTHELIAL ADHESION  
Abstract 
 The major phenolic group of Yak-Kong (Glycine max) especially its seed coat 
is found to be proanthocyanidin. Although clinical studies have shown that intake of 
flavan-3-ol-rich foods is associated with reduced risk of cardiovascular diseases 
(CVDs), it remains unclear which of the metabolic derivatives are responsible for the 
effect. Several metabolomics studies focusing on polymeric flavan-3-ols have reported 
that procyanidins are extensively catabolized by gut microbiota, with 5-(3’,4’-
dihydroxyphenyl)-γ-valerolactone (DHPV) identified as a major microbial metabolite. 
We observed that DHPV has a more potent preventive effect against TNF-α-induced 
THP-1 adhesion to human umbilical vein endothelial cells in comparison to its known 
precursors, including procyanidin A1, A2, B1 and B2, (+)catechin, (-)epicatechin and 
its microbial metabolites 3-(3,4-dihydroxyphenyl)propionic acid and 2-(3,4-
dihydroxyphenyl)acetic acid. Further investigation revealed that DHPV prevents 
monocyte-endothelial cell adhesion by downregulating TNF-α-stimulated expression 
of two biomarkers of atherosclerosis, suggesting that DHPV has relatively high 
potency for the prevention of atherosclerosis compared to other procyanidin 
metabolites. 
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Introduction 
 Retrospective and interventional studies have found evidence for the beneficial 
effects of high flavonoid intake on the prevention of cardiovascular diseases (CVDs) 
(Kay, Hooper, Kroon, Rimm & Cassidy, 2012; McCullough, Peterson, Patel, Jacques, 
Shah & Dwyer, 2012; Wang, Ouyang, Liu & Zhao, 2014). A meta-analysis of human 
randomized controlled trials conducted by Hooper et al. (2008) found that the 
consumption of flavonoid-rich foods strongly correlates with a reduced risk of CVDs 
(Hooper et al., 2008). Specific foods like chocolate, cocoa and black tea are known to 
be a rich source of flavan-3-ols comprising monomeric and polymeric compounds 
(Hooper et al., 2008). Despite promising findings in clinical studies, it remains unclear 
exactly which bioavailable compounds derived from flavan-3-ols exert the most potent 
preventive effects against CVDs. 
 The major phenolic group of Yak-Kong (Glycine max) especially its seed coat 
is found to be proanthocyanidin polymeric flavan-3-ols. Flavan-3-ols are subject to 
several metabolic pathways within the human body (Monagas et al., 2010). The 
bioavailability of flavan-3-ols is highly dependent on their degree of polymerization 
(DP) (Monagas et al., 2010). Polymeric flavan-3-ols (also known as 
proanthocyanidins) have a large molecular size and increased hydrophilicity, thereby 
rendering it difficult for them to penetrate the lipid bilayer of the small intestine 
(Monagas et al., 2010). Proanthocyanidins therefore primarily undergo microbial 
biotransformation in the colon (Ou & Gu, 2014). Among the proanthocyanidin 
subclasses, procyanidin has been widely studied, as it is the most common type found 
in foods including cocoa, chocolate, pine bark extract and grape seed extract (Ou et al., 
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2014; Uhlenhut & Hogger, 2012). Procyanidin is exclusively composed of 
(epi)catechins and is further classified into A and B types, depending on the presence 
of an additional ether bond (Ou et al., 2014). Although metabolites of A and B type 
procyanidins derived from same microbial fermentation show slightly different 
profiles (Sanchez-Patan et al., 2015), metabolomics analyses of both types have 
identified common metabolites such as (epi)catechins, 3-(3’,4’-dihydroxyphenyl)-
propionic acid (DHPA) and 3,4-dihydroxyphenyl-acetic acid (DHAA) (Appeldoorn, 
Vincken, Aura, Hollman & Gruppen, 2009; Sanchez-Patan et al., 2015). 5-(3’,4’-
dihydroxyphenyl)-γ-valerolactone (DHPV) has been recognized as the major 
microbial metabolite of procyanidins and (epi)catechins (Appeldoorn et al., 2009; 
Unno, Tamemoto, Yayabe & Kakuda, 2003). In this study, we sought to investigate 
DHPV in comparison with procyanidin derivatives including A and B type 
procyanidin dimers and other major microbial metabolites for their preventive effect 
on CVDs using a monocyte-endothelial cell adhesion model.  
 
Materials and methods 
 Chemicals and reagents. 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone (DHPV) 
was purchased from Chemieliva Pharmaceutical (Chondquing, China). Procyanidin 
A1 (Pro A1) was purchased from Phytolab (Vestenbergsgreuth, Germany). 
Procyanidin A2 (Pro A2) and Procyanidin B1 (Pro B1) were purchased from 
Extrasynthese (Genay, France). Procyanidin B2 (Pro B2) was purchased from 
Funakoshi (Tokyo, Japan). (+)catechin, (-)epicatechin, 3-(3,4-
dihydroxyphenyl)propionic acid (DHPA), 2-(3,4-dihydroxyphenyl)acetic acid 
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(DHAA), fetal bovine serum (FBS), medium 199 (M199), hydrocortisone, 2-
mercaptoethanol, puromycin and calcein AM solution were purchased from Sigma-
Aldrich (St. Louis, MO, USA). RPMI 1640 medium was purchased from Welgene 
(Daegu, Republic of Korea). Recombinant human epidermal growth factor (hEGF), 
basic fibroblast growth factor (bFGF) and L-glutamine were purchased from Gibco 
(Grand Island, NY, USA). Recombinant human TNF-α (TNF-α) was purchased from 
PeproTech Korea (Seoul, Republic of Korea). Penicillin (10,000 units/ml)-
streptomycin (10,000 µg/ml) (P/S) was purchased from Corning (Corning, NY, USA). 
Antibodies against vascular cell adhesion protein-1 (VCAM-1), β-actin and total I 
kappa-B kinase (IKK)α/β were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Phosphorylated IKKα/β and IκBα and total IκBα were purchased 
from Cell Signaling Biotechnology (Danvers, MA, USA). 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide tetrazolium salt (MTT) solution was purchased 
from USB Corporation (Cleveland, OH, USA). 
 Cell culture. Human umbilical vein endothelial cells (HUVECs) were 
purchased from Lonza (Walkersville, MD, USA) and grown in M199 supplemented 
with 25 mM HEPES containing 10% (v/v) FBS (Gibco), 2 mM L-glutamine, 1 ng/ml 
hydrocortisone, 1% (v/v) P/S and the two growth factors hEGF (1 ng/ml) and bFGF (2 
ng/ml). Stably-transfected HUVECs harboring NF-kB luciferase reporter plasmids 
were cultured with M199 containing 1 μg/ml puromycin. HUVECs between passages 
7 and 12 were used. THP-1 cells, which consist of monocyte-like cells derived from a 
leukemia line, were purchased from the Korean Cell Line Bank and cultured in RPMI 
1640 media supplemented with 10% (v/v) FBS (Sigma-Aldrich), 50 µM 2-
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mercaptoethanol and 1% (v/v) P/S. Subculturing occurred when the density reached 
between 2 x 10
5
 and 1 x 10
6
/ml.  
 Cell viability assay. In 96-well plates, confluent HUVECs were starved with 
serum-free M199 medium containing 2 mM L-glutamine for 4 h. The starved 
HUVECs were treated with various concentrations of procyanidin derivatives 
dissolved in dimethylsulfoxide (DMSO). After 22 h incubation, MTT solution was 
added to the medium at 0.5 mg/ml. At 24 h, 200 µl DMSO was added, and the 
absorbance at 570 nm was measured after 30 min incubation. 
 Monocyte adhesion assay. In 96-well plates, confluent HUVECs were starved 
with serum free M199 containing 2 mM L-glutamine for 4 h. The starved HUVECs 
were treated with proanthocyanidin derivatives in M199 supplemented with 2 mM L-
glutamine and 10% (v/v) FBS for 1 h and then stimulated with 10 ng/ml TNF-α for 5 
h. THP-1 cells were stained with calcein AM and added to the HUVECs at 5 x 10
5
 
cells/well in M199. After 1 h incubation, non-adhered THP-1 cells were washed off 
with phosphate-buffered saline (PBS), and the adhered cells were measured its 
florescence using an Infinite 200 PRO (Tecan group Ltd., Männedorf, Switzerland) at 
excitation and emission wavelengths of 485 nm and 538 nm. 
 Western blot assay. Confluent HUVECs in 6-well plates or 6 cm dishes were 
starved and treated with DHPV at up to 30 μM for 1 h. Pre-treated cells were 
stimulated with 10 ng/ml TNF-α and harvested with RIPA lysis buffer after cold PBS 
washing. Quantified protein lysate samples were separated in 10% sodium dodecyl 
sulfate-polyacrylamide gels and transferred onto polyvinylidene difluoride 
membranes. The membranes were blocked and incubated with specific primary 
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antibodies at 4 °C overnight. Horseradish peroxidase-conjugated secondary antibodies 
were added for 1 h, and the protein bands were then visualized using an enhanced 
chemiluminescence detection kit (GE Healthcare, London, UK). 
 The enzyme-linked immunosorbent assay for MCP-1. Following DHPV 
pretreatment and TNF-α-stimulation, protein levels of MCP-1 in the HUVEC culture 
supernatant were measured using Human MCP-1/CCL2 ELISA MAX Deluxe Sets 
(BioLegend, San Diego, CA, USA). Briefly, 100 μl of standard cytokines or diluted 
culture supernatants were added to each well of an MCP-1 antibody-coated 96-well 
plate and incubated for 2 h at room temperature. Each well was incubated with the 
detection antibody for 1 h followed by Avidin-HRP solution together with the 
substrate solution for 30 min and 20 min, respectively. Appropriate washing was 
performed between each addition of solution. The optical density of each well was 
determined using a microplate reader at 450 nm and 570 nm. A standard curve for the 
cytokine was generated, and linear regression analysis was performed. 
Real-time quantitative PCR. Total RNA was extracted from HUVECs using 
Trizol and RNA iso Plus (Takara Bio Inc., Shiga, Japan), and quantified using a 
NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA). cDNAs were synthesized from a total of 1 μg/μl RNA using a PrimeScriptTM 1st 
strand cDNA Synthesis Kit (Takara Bio Inc., Shiga, Japan). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was selected as an internal standard. The cDNAs 
were probed using the following primers (Bioneer, Daejeon, Korea): human VCAM-1 
forward (5’- CCC TCC CAG GCA CAC ACA -3’); human VCAM-1 reverse (5’- 
GAT CAC GAC CAT CTT CCC AGG -3’); human MCP-1 forward (5’- TCG CCT 
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CCA GCA TGA AAG TC -3’); human MCP-1 reverse (5’- GGC ATT GAT TGC 
ATC TGG CT -3’); human GAPDH forward (5’- CAG GGC TGC TTT TAA CTC 
TGG TAA A -3’); human GAPDH reverse (5’- GGG TGG AAT CAT ATT GGA 
ACA TGT AA -3’). For quantitative real-time PCR, iQTM SYBR Green®  Supermix 
and a CFX Connect
TM
 Real-time PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA, USA) were used.  
 Luciferase Assay for NF-kB transactivation. The lentiviral expression vector 
pGF1-NF-kB-EF1-Puro (System Biosciences, Palo Alto, CA, USA) was transfected 
into HEK293T cells with the packaging vectors pMD2.G and psPAX2 (Addgene, 
Cambridge, MA, USA) using JetPEI DNA transfection reagent (Polyplus-transfection, 
New York, NY, USA). HUVECs were transfected using filtered transfection medium 
harvested from the HEK293T cell culture and 10 μg/ml polybrene (EMD Millipore, 
Billerica, MA, USA). After selection with 1 μg/ml puromycin (InvivoGen, San Diego, 
CA, USA) stably-transfected HUVECs were seeded at 1 x 10
4
 cells/well in 96-well 
plates. After 4 h starvation, the cells were pretreated with DHPV at up to 30 μM for 1 
h before stimulation with 10 ng/ml TNF-α. After 10 h stimulation, the cells were 
disrupted with lysis buffer (0.1 M pH 7.8 PBS, 1% Triton X-100, 1 mM DTT and 2 
mM EDTA), and luciferase activity was measured using a Luminoskan Ascent 
(Thermo Electron, Helsinki, Finland). 
Statistical analysis. Statistical analyses were performed using SPSS 
(Statistical Analysis System Institute, 2010). Significant differences between the 
means were determined using Tukey’s Honest Significant Difference test at P < 0.05. 
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Results 
 DHPV exerts superior preventive effects against TNF-α stimulated 
monocyte-endothelial adhesion compared to other procyanidin derivatives. Major 
procyanidin derivatives were selected based on previous studies (Figure 3.1). To 
investigate the preventive effect of the compounds against atherosclerosis, we 
pretreated HUVECs with 30 μM of procyanidin dimers (Pro A1, Pro A2, Pro B1 and 
Pro B2), monomers ((-) epicatechin and (+)-catechin) or their microbial metabolites 
including DHPV, DHPA and DHAA for 1 h prior to TNF-α stimulation. Compared to 
the selected procyanidin derivatives, DHPV significantly prevented THP-1 adhesion 
to TNF-α-stimulated HUVECs in a dose-dependent manner (Figure 3.2A). 
Concentrations of the procyanidin derivatives up to 30 μM did not compromise cell 
viability (Figure 3.2B). 
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Figure 3.1. Procyanidin microbial catabolism. 
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Figure 3.2. Comparison of monocyte-endothelial adhesion inhibitory effects between DHPV and other procyanidin microbial 
metabolites. (A) Following pretreatment of procyanidin derivatives at the indicated concentrations for 1 h, HUVECs were exposed 
to TNF-α for a further 5 h. Calcein AM-labeled THP-1 was then added to the HUVEC medium and for 1 h to allow for adherence. 
The number of adhered THP-1 cells was determined with a fluorescence microplate reader at excitation and emission wavelengths 
of 485 and 535 nm, respectively. Images were captured with a fluorescence microscope. (B) Varying concentrations of DHPV and 
30 μM of various other procyanidin microbial metabolites were tested for cytotoxicity. Data are expressed as means ± SD (n = 4). 
Different letters denote significant differences (P < 0.05); values bearing the same letters are not significantly different from each 
other. 
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 DHPV attenuates TNF-α-stimulated upregulation of VCAM-1 mRNA and 
protein expression. We sought to evaluate whether DHPV may be exerting 
preventive effects on TNF-α-stimulated monocyte-endothelial adhesion through the 
suppression VCAM-1. Western blot analysis and RT-qPCR showed that DHPV 
prevented VCAM-1 expression at both the mRNA and protein levels in TNF-α-
stimulated HUVECs in a dose-dependent manner (Figure 3.3A & B).  
 
 
 
 
Figure 3.3. Effect of DHPV on VCAM-1 expression in TNF-α-stimulated HUVECs. 
Preventive effect of DHPV on TNF-α-stimulated (A) VCAM-1 protein expression as 
assessed by Western blot. Data are expressed as means ± SD (n = 3) (B) VCAM-1 
mRNA expression was measured by RT-qPCR. Data are expressed as means ± SD (n 
= 4). Different letters denote significant differences (P < 0.05); values bearing the 
same letters are not significantly different from each other. 
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 DHPV attenuates TNF-α-stimulated upregulation of MCP-1 at mRNA 
and protein levels. To investigate whether DHPV treatment can prevent monocytes 
from migrating into the vascular intima while they are adhered to the vascular 
endothelium, the secretion of MCP-1 protein was quantified in TNF-α-stimulated 
HUVEC culture supernatants by ELISA. DHPV pretreatment attenuated TNF-α-
stimulated MCP-1 protein secretion as well as mRNA expression in these cells (Fig. 
3.4A & B).  
 
 
 
Figure 3.4. Effect of DHPV on MCP-1 expression in TNF-α-stimulated HUVECs. 
Preventive effect of DHPV on TNF-α-stimulated (A) MCP-1 protein secretion as 
assessed by ELISA. (B) MCP-1 mRNA expression was analyzed by RT-qPCR. Data 
are expressed as means ± SD (n = 4). Different letters denote significant differences (P 
< 0.05); values bearing the same letters are not significantly different from each other. 
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 DHPV suppresses TNF-α-stimulated activation of NF-κB in HUVECs. To 
determine whether the preventive effect of DHPV on TNF-α-stimulated expression of 
VCAM-1 and MCP-1 is associated with the inhibition of NF-κB, we analyzed NF-κB 
transactivation in HUVECs stably transfected with NF-κB luciferase reporter 
plasmids. Pretreatment with DHPV significantly suppressed TNF-α-stimulated 
transcriptional activation of NF-κB (Fig. 3.5) in a dose-dependent manner. 
 
 
 
Figure 3.5. Effect of DHPV on TNF-α-induced NF-κB transcriptional activity. 
Following pretreatment with DHPV and TNF-α-stimulation, NF-κB transcriptional 
activity was measured in HUVECs transfected with NF-κB luciferase reporter 
plasmids. Data are expressed as means ± SD (n = 4). Different letters denote 
significant differences (P < 0.05); values bearing the same letters are not significantly 
different from each other. 
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 DHPV suppresses TNF-α-stimulated phosphorylation of proteins involved 
in NF-kB signaling in HUVECs. To further elucidate the manner in which DHPV 
modulates NF-κB activity, we examined the preventive effect of DHPV on TNF-α-
induced phosphorylation of IKK and IκBα, two key regulators of NF-κB activation. 
We observed that DHPV downregulated TNF-α-stimulated phosphorylation of IKK in 
a concentration-dependent manner as well as IκBα, a downstream effector of IKK 
(Fig. 3.6). DHPV also prevented degradation of IκBα following TNF-α-stimulation 
(Fig. 3.6). 
 
 
 
 
Figure 3.6. Effect of DHPV on TNF-α-stimulated NF-κB signaling. Expression of 
phosphorylated and unphosphorylated proteins comprising the NF-κB signaling 
pathway as determined by Western blot. 
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Discussion 
Several metabolomics studies have shed light on the potential metabolic 
pathways responsible for the microbial catabolism of procyanidins (Fig. 3.1) 
(Appeldoorn et al., 2009). Gut microflora can cleave the strong interflavan bonds 
within procyanidins to produce (epi)catechin-monomer building blocks (Bittner, 
Kemme, Peters, Kersten, Danicke & Humpf, 2014) with a slow reaction rate 
(Appeldoorn et al., 2009; Stoupi, Williamson, Drynan, Barron & Clifford, 2010). It 
appears that the A- & C-rings in (epi)catechins and procyanidins are primarily targeted 
by microbiota (Appeldoorn et al., 2009; Ou et al., 2014). Two human intestinal 
bacterial species, Eggerthella lenta rK3 and Eubacterium (E.) sp. Strain SDG-2, were 
found to cleave C-rings in (epi)catechins (Kutschera, Engst, Blaut & Braune, 2011; 
Wang et al., 2001). In addition, Flavonifractor plautii aK2 further converts the C-ring-
cleaved intermediate into DHPV via A-ring breakdown and lactone formation 
(Kutschera et al., 2011). DHPV may also be directly derived from breakdown of the 
A-ring in procyanidins (Appeldoorn et al., 2009). DHPV is further degraded into 
DHPA and DHAA via β- and α-oxidation, respectively (Ou et al., 2014). These 
metabolites have been found in human biological fluids, and procyanidin dimers such 
as A2 (Zampariello, Mckay, Dolnikowski, Blumberg & Chen, 2012), B1 (Sano, 
Yamakoshi, Tokutake, Tobe, Kubota & Kikuchi, 2003) and B2 (Holt et al., 2002), 
(epi)catechins (Richelle, Tavazzi, Enslen & Offord, 1999), DHPV (Urpi-Sarda et al., 
2009) and DHAA (Bartolome et al., 2010; Saura-Calixto et al., 2010) have been 
identified in human blood plasma after intake of procyanidin-rich foods. In contrast to 
DHPA and DHAA, which can be derived from the microbial catabolism of other 
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flavonoid subclasses (Serra, Macia, Romero, Reguant, Ortega & Motilva, 2012), 
DHPV has been exclusively detected in human biological fluids after consumption of 
(epi)catechin-rich green tea (Li et al., 2000), proanthocynidin-rich cocoa (Urpi-Sarda 
et al., 2009; Urpi-Sarda et al., 2009), and pycnogenol (Grimm et al., 2006). Despite 
the importance of DHPV in procyanidin catabolism, little research has been focused 
on the properties of DHPV, such as its anti-inflammatory activity. DHPV exhibits 
stronger inhibitory activity than its precursor catechin on LPS-induced nitric oxide 
production in RAW 264.7 macrophages and the key enzymes of inflammatory and 
degenerative disorders, such as the matrix metalloproteinases (Grimm, Schafer & 
Hogger, 2004; Uhlenhut et al., 2012). In addition, DHPV exhibits more potent radical 
scavenging and antioxidative activities than catechin and vitamin C (Grimm et al., 
2004). The present study marks the first report of the potential cardioprotective effects 
of DHPV. 
Atherosclerosis is a major cause of CVDs and is thought to be highly 
preventable, particularly through adherence to a healthy diet (Mendis, Puska, 
Norrving, World Health Organization, World Heart Federation, & World Stroke 
Organization, 2011). In the early stages of atherosclerosis, vascular endothelial cells 
under inflammatory conditions begin to attract leukocytes such as monocytes (Libby, 
2006; Libby, Ridker & Maseri, 2002; Ross, 1999). It has been well established that 
VCAM-1 and MCP-1 in the vascular endothelial cells are the key drivers of 
monocyte-endothelial adhesion (Tedgui & Mallat, 2006). VCAM-1 integrin is 
reported to be the critical mediator that strongly binds monocytes (Libby, 2006). After 
integrin-monocyte binding, inflammatory conditions continue to activate the 
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chemokine MCP-1, which attracts further monocytes into the vascular intima (Libby, 
2006). Proinflammatory cytokines such as TNF-α stimulate a phosphorylation cascade 
within the IκB/NF-κB pathway, and the translocation of NF-κB into the nucleus 
activates transcription of numerous genes, including pro-inflammatory cytokines, 
adhesion molecules and chemokines (Libby, 2006; Libby et al., 2002; Tedgui et al., 
2006). It has been previously reported that frequent consumption of procyanidin-rich 
cocoa improves vascular endothelial function and reduces levels of soluble adhesion 
molecules in the plasma of individuals who are at a high-risk of CVDs (Monagas et 
al., 2009; Wang-Polagruto et al., 2006). Several other in vivo and in vitro studies have 
shown that procyanidin-rich extracts reduce levels of VCAM-1 and MCP-1 under 
inflammatory conditions (Mohana, Navin, Jamuna, Sadullah & Devaraj, 2015; Zhang, 
Li & Li, 2016) (Sen & Bagchi, 2001). Other studies focusing on (epi)catechin 
metabolites have reported that both epicatechin phase II metabolites (Claude et al., 
2014) and rat plasma after intake of (+)catechin (Koga & Meydani, 2001) inhibits 
monocyte-endothelial adhesion. In the case of DHPV, a single study has shown that 
the plasma of human volunteers containing DHPV after intake of pycnogenol inhibits 
NF-κB activation and MMP-9 secretion in activated human monocytes (Grimm et al., 
2006). The present study marks the first report showing that DHPV has the most 
potent preventive effects on TNF-α-stimulated monocyte-endothelial adhesion among 
the procyanidin derivatives, downregulates two prominent biomarkers of 
atherosclerosis (VCAM-1 and MCP-1), activates NF-κB transcription, and 
phosphorylates IKK and IκBα. Further kinase targets of DHPV need to be identified in 
order to elucidate its full effects on atherosclerosis prevention.  
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Conclusion 
Metabolomics studies have supported the notion that DHPV is a biologically 
important microbial metabolite exclusively derived from flavan-3-ols. Several DHPV-
producing gut microbiota have been identified as well. Our findings suggest that 
DHPV may be a primary contributor toward the preventive effects of procyanidins on 
CVDs that have been observed in clinical studies. Further studies on the reduced risk 
of CVDs from chronic procyanidin intake and the presence of DHPV-producing 
microbiota, correlating with bioavailable DHPV levels in plasma are warranted.  
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CHAPTER 4 
A MAJOR DAIDZEIN METABOLITE 7,8,4’-TRIHYDROXYISOFLAVONE 
FOUND IN THE PLASMA OF YAK-KONG EMBRYO EXTRACT-FED RATS 
ATTENUATES MONOCYTE-ENDOTHELIAL CELL ADHESION 
Abstract 
 Among many functional foods and their phytochemicals, ingestion of soybean 
is highly correlated to reduced risk of cardiovascular diseases (CVDs). Validation of 
potential health benefits of functional foods requires information about the 
bioavailability and metabolism of bioactive compounds. In this context, hydroxylated 
metabolites of isoflavones were target-analyzed in the plasma of rats acutely 
supplemented with Yak-Kong embryo (YKE) extract. A daidzein metabolite, 7,8,4’-
trihydroxyisoflavone (7,8,4’-THI), was detected at the highest concentration (average 
5.1 μM). Therefore, its potential prevention effect on atherosclerosis was investigated 
using monocyte-endothelial cell adhesion assay. Different from its precursor daidzein 
or daidzin, 7,8,4’-THI attenuated adhesion of THP-1 monocytes to TNF-α stimulated 
human umbilical vein endothelial cells. In addition, 7,8,4’-THI significantly 
downregulated the expression of vascular cell adhesion molecule-1 and monocyte 
chemotactic protein-1 and phosphorylation of IκB kinase and IκBα involved in the 
initiation of atherosclerosis. Therefore, 7,8,4’-THI, a highly bioavailable hydroxylated 
isoflavone metabolite, has potential anti-atherosclerotic effect via inhibiting 
monocyte-endothelial adhesion.  
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Introduction 
 Among many functional foods and their phytochemicals, consumption of 
soybean (Glycine max), especially its two functional constituents (protein and 
isoflavones), is highly correlated with reduced risk of cardiovascular diseases (CVDs) 
(Zhan & Ho, 2005). However, it is currently unclear which isoflavone is highly 
bioavailable in our body after soybean intake to exert the bioactivity for CVD 
prevention. Validation of potential health benefits of functional foods requires 
information about the bioavailability and metabolism of bioactive compounds because 
native compounds found in plants are recognized as xenobiotics in human body. They 
go through structural changes via several metabolic reactions such as phase I and II 
metabolisms (Cassidy & Minihane, 2017). Most dietary flavonoids are first subjected 
to enzymatic hydrolysis since their glycoside conjugates are too hydrophilic to be 
absorbed by the small intestine (Chen, Zheng, Li & Jiang, 2014). In enterocytes, 
absorbed aglycones will mainly undergo phase II reactions such as methylation, 
sulfation, and glucuronidation involving catechol-O-methyltransferases, 
sulfotransferases and uridine-5’-diphosphate glucuronosyltransferases, respectively 
(Chen et al., 2014). Absorbed conjugates or aglycones are then transported to the liver 
via portal vein for further phase II metabolism (Cassidy et al., 2017; Chen et al., 
2014). In addition to phase II metabolism, hydrolyzed flavonoids after absorption will 
undergo phase I metabolism such as hydroxylation and demethylation involving 
cytochrome P450 (Cassidy et al., 2017; Chen et al., 2014). Some metabolites can be 
effluxed back to the intestinal lumen directly or through bile (Cassidy et al., 2017; 
Chen et al., 2014). Flavonoids that cannot be absorbed in the small intestine and 
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effluxed metabolites will reach the large intestine where they are extensively 
metabolized by gut microbiota (Cassidy et al., 2017; Chen et al., 2014). 
 For many years, researches in metabolomics of isoflavones have been focused 
on aglycones, mostly genistein and daidzein, and their reductive metabolites such as 
equol (Manach, Williamson, Morand, Scalbert & Remesy, 2005). Among the reported 
bioavailable metabolites of isoflavones, hydroxylated isoflavones have shown stronger 
antioxidant activity against lipid peroxidation than its precursors (Esaki, Onozaki, 
Morimitsu, Kawakishi & Osawa, 1998). In this study, isoflavone aglycones and their 
phase I metabolites especially hydroxylated metabolites were target-analyzed in the 
plasma of rats fed with Yak-Kong embryo (YKE) extract and the potential anti-
atherosclerotic effect of major circulating metabolite was compared to that of its 
precursors. 
 
Materials and methods 
 Chemicals and reagents. 7,8,4’-trihydroxyisoflavone (7,8,4’-THI) was 
purchased from Indofine Chemical Company (Hillsborough, NJ, USA). Isoflavone 
standards (daidzin, daidzein, genistein, and coumestrol), medium199 (M199), 
hydrocortisone, fetal bovine serum (FBS), and calcein AM dye were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). RPMI 1640 medium was purchased from 
Welgene (Daegu, Republic of Korea). L-glutamine, basic fibroblast growth factor 
(bFGF), and recombinant human epidermal growth factor (hEGF) were purchased 
from Gibco (Grand Island, NY, USA). Penicillin (10,000 units/ml)-streptomycin 
(10,000 µg/ml) (P/S) was purchased from Corning (Corning, NY, USA). Tumor 
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necrosis factor-alpha (TNF-α) was purchased from PeproTech Korea (Seoul, Republic 
of Korea). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium 
salt (MTT) solution was purchased from USB Corporation (Cleveland, OH, USA). 
Dimethylsulfoxide (DMSO) was purchased from Duksan Pure Chemicals (Ansan, 
Republic of Korea). Antibodies against vascular cell adhesion molecule-1 (VCAM-1) 
and β-actin were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, 
USA). Phosphorylated and basal IκB kinase (IKK) and IκBα were purchased from 
Cell Signaling Biotechnology (Danvers, MA, USA). Liquid chromatography grade 
solvents such as acetone and acetonitrile were purchased from EMD Millipore 
Chemicals (Billerica, MA, USA). Glacial acetic acid, formic acid, and phosphoric acid 
were obtained from Anachemia (Lachine, QC, Canada). All other analytical chemicals 
were purchased from Merck KGaA (Darmstad, Germany). 
 Animal study and plasma preparation. Twenty male Wistar rats (Charles 
River, St. Constant, QC, Canada) were placed in temperature- and humidity-controlled 
rooms (21 ± 2 °C, 35−40%) with a daily light-dark cycle of 12 h−12 h. Animal 
facilities met the guidelines of the Canadian Council on Animal Care. Protocols were 
approved by the Animal Care Committee of Laval University (reference CPAUL 
2015-137-1). Animals were acclimated to their environment for a minimum of 5 days. 
They were provided ad libitum access to nonpurified rodent diet (rodent chow no. 
2918, Harlan Teklad, Madison, WI, USA). All animals had continuous access to tap 
water. After the acclimation period, rats were fed a soybean excluded diet (AIN-76A, 
Envigo Teklad Diets, Madison, WI, USA) for 3 days. The day before the test, rats 
were fasted for 12 h and randomly allocated to two groups (10 rats per group). The 
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YKE group was administered a single dose of YKE extract with an average intake of 
12 mg/kg body weight (BW) of isoflavones while the control group was only 
administered vehicle (water) by intragastric gavage. Blood samples were collected 
from the saphenous vein using EDTA-containing syringes (Sarstedt Microvettes) at 
time 0 (pre-ingestion) and at 30, 60, 120, and 240 min post-ingestion. Plasma samples 
were obtained by centrifugation (1,100 x g, 10 min at 4 °C) and stored at −80 °C until 
analysis. 
 Isoflavones metabolites were extracted from plasma as previously described by 
Dudonné et al. with slight modifications. Briefly, Waters OASIS HLB micro-elution 
plates 2 mg–30 mm were preconditioned using 250 µl of methanol and 250 µl of 0.2% 
acetic acid. Plasma samples were mixed with 4% phosphoric acid in ultrapure water 
(v/v) to disrupt phenol-protein binding before loading into plates. Loaded plates were 
washed with 200 µl of ultrapure water and 200 µl of 0.2% acetic acid. Retained 
phenolic compounds were eluted with 75 µl of acetone/ultrapure water/acetic acid 
solution (70/29.5/0.5, v/v/v). Eluted phenolic metabolites were then directly analyzed 
by UHPLC−MS/MS. 
 Targeted analysis of isoflavone metabolites in plasma. Isoflavone 
metabolites were analyzed by reverse-phase UHPLC coupled to tandem mass 
spectrometry. Separation was achieved at 45 °C with a Waters Acquity HSS T3 
column (2.1 mm x 100 mm, 1.8 µm) at  a flow rate of 0.45 ml/min and an injection 
volume of 2.5 µl. Gradient elution was performed with a mobile phase consisted of 
0.2% acetic acid in ultrapure water and acetonitrile (solvent A and B, respectively) 
using the following conditions: 0–0.5 min, 5% B; 0.5–1 min, 5–25% B; 1–3 min, 25–
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45% B; 3–4.5 min, 45–55% B; 4.5–4.7 min, 55–100% B. MS/MS analyses were 
carried out in negative mode using electrospray source parameters as follows: 
electrospray capillary voltage, 1.3 kV; source temperature, 150 °C; desolvation 
temperature, 400 °C; cone and desolvation gas flows, 50 and 800 l/h, respectively. 
Data were acquired at multiple reaction monitoring (MRM) mode to track specific 
parent-product ion transition of the following compounds: genistein, daidzein, 
glycitein, orobol, 6,7,4’-THI, 7,3’,4-THI and 7,8,4’-THI. Cone voltage and collision 
energy were optimized for each compound.  
 The identification of metabolites was validated by comparing their retention 
times and molecular ions with those of available standards or with fragmentation 
information described in literatures otherwise. External quantification was achieved 
using calibration curves constructed with available standards. Parent/product ion pairs 
(MRM transitions) and standards used for the quantification of identified metabolites 
are summarized in Table 4.1. 
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Table 4.1. Targeted analysis of isoflavone metabolites in plasma of rats supplemented with YKE extract.
a 
a
 Data are displayed as means of replicates ± SEM (n=10). 
b
 ND = not detected. *, P < 0.005. 
 
 
Isoflavones metabolites 
MRM 
transitions 
Standard for quantification 
Concentrations in plasma 
(AUC) 
Control Embryo 
Genistein (5,7,4'-trihydroxyisoflavone) 269 > 169 - ND
b
 ND 
Daidzein (7,4'-dihydroxyisoflavone) 253 > 91 Daidzein ND 42.5 ± 6.7* 
Glycitein (7,4'-dihydroxyisoflavone-6-methoxyisoflavone) 283 > 184 - ND ND 
Orobol (5,7,3',4'-tetrahydroxyisoflavone) 285 > 148 - ND ND 
6,7,4'-trihydroxyisoflavone 269 > 169 - ND ND 
7,3',4'-trihydroxyisoflavone 269 > 169 - ND ND 
7,8,4'-trihydroxyisoflavone 269 > 169 7,8,4'-trihydroxyisoflavone ND 574.3 ± 112.8* 
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 Cell culture. Human umbilical vein endothelial cells (HUVECs) were 
purchased from Lonza (Walkersville, MD, USA). HUVECs (passage between 7 and 
14) were grown in M199 with 25 mM HEPES containing 10% FBS, 2 mM L-
glutamine, 1 ng/ml hydrocortisone, 1% (v/v) P/S, 1 ng/ml hEGF and 2 ng/ml bFGF. 
THP-1 cells, monocyte-like leukemia derived cells, were purchased from the Korean 
Cell Line Bank. THP-1 cells were grown in RPMI1640 supplemented with 10% FBS, 
50 µM 2-mercaptoethanol and 1% (v/v) P/S. THP-1 cell subculture was conducted 
when its density reached between 2 x 10
5
 and 1 x 10
6
 cells/ml. For in vitro cell 
experiments, stock solutions were prepared in DMSO. 
 Cell viability assay. Confluent HUVECs were starved with serum free M199 
containing 2 mM L-glutamine for 4 h and were incubated with different 
concentrations of isoflavone metabolites. After 22 h incubation, MTT solution was 
added. After additional 2 h incubation, DMSO was added, and the absorbance was 
measured at 570 nm. 
 Monocyte-endothelial cell adhesion assay. Starved HUVECs were pretreated 
with a non-toxic dosage of isoflavone metabolites for 1 h and then stimulated with 10 
ng/ml TNF-α for 5 h. Calcein AM stained-THP-1 cells (5 x 105/well) were then 
layered over the HUVEC monolayers. After 1 h incubation, the non-adhered cells 
were washed off with PBS, and the fluorescence was measured using an Infinite 200 
PRO system (Tecan group Ltd., Männedorf, Switzerland) at excitation and emission 
wavelengths of 485 nm and 538 nm. 
 Western blot assay. Confluent HUVECs were starved and treated with 
isoflavones for 1 h and stimulated with 10 ng/ml TNF-α. At various time points, cells 
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were scraped and disrupted with lysis buffer to obtain cell lysates. Equal amounts of 
proteins in lysate samples were subjected to 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to polyvibylidene difluoride 
membrane. After incubating the membrane with specific primary antibodies at 4 °C 
overnight and horseradish peroxidase-conjugated secondary antibodies, protein bands 
were visualized using enhanced chemiluminescence detection kit (Amersham 
Pharmacia Biotech, Piscataway, NJ, USA). 
 Enzyme-linked immunosorbent assay. Levels of monocyte chemoattractant 
protein-1 (MCP-1) in culture supernatant were determined using Human MCP-
1/CCL2 ELISA MAX Deluxe Sets (BioLegend, San Diego, CA, USA) according to 
the manufacturer’s protocol.  
 Real-time quantitative PCR. Total RNA was extracted from HUVECs and 
quantified. Primers of human VCAM-1 forward (5’-CCC TCC CAG GCA CAC 
ACA-3’), human VCAM-1 reverse (5’-GAT CAC GAC CAT CTT CCC AGG-3’), 
human MCP-1 forward (5’-TCG CCT CCA GCA TGA AAG TC-3’), human MCP-1 
reverse (5’-GGC ATT GAT TGC ATC TGG CT-3’), human GAPDH forward (5’-
CAG GGC TGC TTT TAA CTC TGG TAA A-3’), human GAPDH reverse (5’-GGG 
TGG AAT CAT ATT GGA ACA TGT AA-3’) were used for running a quantitative 
real-time PCR. The amount of target gene expression was calculated as a ratio of the 
target transcript relative to GAPDH in each sample. 
 Statistical analyses. Area under plasma concentration (μM) time (min) curve 
(AUC) of isoflavone metabolites was calculated according to linear trapezoidal rule. 
Plasma concentrations of isoflavone metabolites detected in supplemented rats 
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(expressed as AUC) were compared to those of control rats using Welch’s t-test 
(correcting for unequal variance) when data were normally distributed or Mann–
Whitney test otherwise (GraphPad Prism 6.05, La Jolla, CA, USA). Biological results 
were compared using SPSS (Statistical Analysis System Institute, 2010). Significance 
of difference among means was determined by Tukey’s Honest Significant Difference 
test. Statistical significance was set at P < 0.05. 
 
Results 
 7,8,4’-THI was detected as the major isoflavone metabolite in rat plasma 
after intake of YKE extract. Isoflavone compositions of YKE extract are shown in 
Chapter II. Table 2.1. Among derivatives of genistin, daidzin, and glycitin, genistin 
derivatives including its acetyl, malonyl, and aglycon forms were the main 
isoflavones, accounting for more than 50% of isoflavones found in the YKE extract. 
 Targeted metabolomics analysis of the plasma of rats following their 
administration of around 12 mg of isoflavone content/kg BW revealed the presence of 
daidzein and 7,8,4’-THI (Table 4.1). 7,8,4’-THI was found to have the highest average 
AUC value (574.3 ± 112.8), which was at least 10 times higher than its precursor 
daidzein (average AUC 42.5 ± 6.7). Kinetic profiles of 7,8,4’-THI and daidzein are 
shown in Figure 4.1. 7,8,4-THI was detected in micro molar concentration ranges, 
with the highest average 5.1 µM within 30–60 min. Plasma levels of this metabolite 
started to decrease after it reached the highest peak within 60 min. 
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Figure 4.1. Plasma kinetic profile of daidzein (A) and its hydroxylated metabolite 7,8,4’-THI (B) in rats acutely treated with SE 
extract. Data are displayed as means ± SEM (n = 10). 
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 7,8,4’-THI exerts stronger inhibitory effects on cell adhesion of THP-1 to 
TNF-α-stimulated HUVECs in comparison with its precursor daidzein or 
daidzin. Prevention effect of 7,8,4’-THI on atherosclerosis was evaluated in vitro 
using THP-1-HUVEC co-culture system. One hour before TNF-α stimulation, 
HUVECs were pretreated with 7,8,4’-THI or its precursor daidzein or daidzin for 
comparison (Figure 4.2A). Different from daidzein or daidzin, 7,8,4’-THI showed 
inhibitory effect on adhesion of THP-1 to TNF-α stimulated HUVECs in a dose-
dependent manner (Fig. 4.2B). In addition, treatment concentrations of each 
compound did not show any cytotoxicity to HUVECs within 24 h (Figure 4.2C). 
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Figure 4.2. Comparison of monocyte-endothelial adhesion inhibitory effect between 
7,8,4’-THI and its precursors daidzein and daidzin. (A) Structure of 7,8,4’-THI, 
daidzein, and daidzin (Left to right). (B) Representative images of calcein AM-labeled 
THP-1 in different treatment groups. Quantification of adhered THP-1 cells was 
described in the Materials and Methods. (C) Cell cytotoxicity was evaluated by MTT 
assay. Data are expressed as means ± SD (n = 4). Different letters denote significant 
differences (P < 0.05). Values bearing the same letters are not significantly different 
from one another. 
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 7,8,4’-THI suppresses VCAM-1 and MCP-1 expression in TNF-α-induced 
HUVECs. Prevention effect of 7,8,4’-THI on TNF-α stimulated expression of 
VCAM-1 and MCP-1 in HUVECs was evaluated in order to examine proinflammatory 
cytokine stimulated mechanism involved in monocyte-endothelial adhesion. Western 
blot analysis showed that pretreatment with 7,8,4’-THI downregulated protein 
expression levels of TNF-α stimulated VCAM-1 in a dose dependent manner (Figure 
4.3A). ELISA results showed that TNF-α stimulated MCP-1 protein secretion into the 
medium was reduced by pretreatment with 7,8,4’-THI (Figure 4.3B). In addition, RT-
qPCR results showed that pretreatment with 7,8,4’-THI attenuated mRNA expression 
levels of TNF-α-stimulated VCAM-1 (Figure 4.3C) and MCP-1 (Figure 4.3D) in a 
dose-dependent manner. 
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Figure 4.3. Effect of 7,8,4’-THI on VCAM-1 and MCP-1 expression levels in TNF-α-
stimulated HUVECs. (A) Western blot analysis showing the effect of 7,8,4’-THI on 
TNF-α-stimulated VCAM-1 protein expression. (B) RT-qPCR showing the effect of 
7,8,4’-THI on TNF-α-stimulated VCAM-1 mRNA expression. (C) ELISA analysis 
showing the effect of 7,8,4’-THI on TNF-α-stimulated MCP-1 protein expression. (D) 
RT-qPCR showing the effect of 7,8,4’-THI on TNF-α-stimulated MCP-1 mRNA 
expression. All the data is expressed as means ± SD of three or four independent 
experimental replications. Different letters denote significant differences (P < 0.05). 
Values bearing the same letters are not significantly different from one another. 
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 7,8,4’-THI regulates NF-κB signaling in TNF-α-induced HUVECs. 
Prevention effect of 7,8,4’-THI on TNF-α stimulated phosphorylation of IKK and 
IκBα in HUVECs was investigated to understand proinflammatory cytokine 
stimulated expression of VCAM-1 and MCP-1 as well as NF-κB signaling pathway. 
7,8,4’-THI downregulated TNF-α stimulated phosphorylation of IKK (Figure 4.4A) 
and its downstream signaling protein IκBα (Figure 4.4B). Reduction of basal 
expression of IκBα caused by TNF-α stimulation was prevented by 7,8,4’-THI 
pretreatment as its concentration was increased (Figure 4.4C).  
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Figure 4.4. Effect of 7,8,4’-THI on NF-κB signaling in TNF-α-stimulated HUVECs. 
Western blot analyses show the effect of 7,8,4’-THI on TNF-α-stimulated (A) 
phosphorylated and total protein expression levels of IKK, (B) phosphorylated IκBα 
and (C) total protein expression levels of IκBα. All the data is expressed as means ± 
SD of three independent experimental replications. Different letters denote significant 
differences (P < 0.05). Values bearing the same letters are not significantly different 
from one another. 
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Discussion 
 A meta-analysis conducted by Zhan and Ho (2005) has found that intake of 
regular soy protein (Glycine max) together with a higher dose of isoflavone (80-185 
mg/day) has higher impact on risk factors of CVDs compared to soy protein intake 
without isoflavones or lower doses of isoflavones (20-80 mg/day). However, native 
isoflavones are subjected to several metabolic biotransformation, leading to phase I 
and II metabolites (Barnes et al., 2011). Metabolites of isoflavones might have 
additive or synergistic effect on the potential preventive bioactivity of soy protein for 
CVDs. In the present study, rats were administered with YKE extract at an average of 
12 mg of isoflavones per kg BW corresponding to human intake of about 110 mg 
isoflavones per 60 kg BW according to body surface area normalization (FDA, 2005). 
Following this acute supplementation, 7,8,4’-THI was found as the major circulating 
metabolite of isoflavone. 
 It has been previously reported that isoflavone aglycones are predominantly 
hydroxylated at ortho positions to original hydroxyl groups (Kulling, Honig, Simat & 
Metzler, 2000). It has been further found that 5,7,3’4’-tetrahidroxyisoflavone, 7,3’,4’-
THI, 6,7,4’-THI, and 7,8,4’-THI are four major hydroxylated metabolites of 
isoflavones found in human urine (Heinonen, Hoikkala, Wahala & Adlercreutz, 2003). 
Additionally, pharmacokinetic study of daidzein in humans has confirmed that these 
hydroxylated metabolites of daidzein are present in both urine and plasma at nano-
molar concentrations after the intake of a single dose of daidzein (Rufer, Bub, 
Moseneder, Winterhalter, Sturtz & Kulling, 2008). 5,7,3’4’-tetrahidroxyisoflavone has 
been identified as the major hydroxylated metabolite of genistein (Kulling et al., 
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2000). These metabolites are derived from both gut microbiota (Heinonen, Wahala, 
Liukkonen, Aura, Poutanen & Adlercreutz, 2004) and cytochrome P450 (Kulling, 
Honig & Metzler, 2001) specifically CYP1A2 P450 isozyme (Peng, Wang, Li, Abd 
El-Aty, Chen & Zhou, 2003). Inter-individual variability in gut microbiota and 
cytochrome P450 (Chen, Zhang, Huang & Cai, 2016; Poolsup, Po & Knight, 2000) 
can affect individual responses in producing different profiles of hydroxylated 
metabolites of isoflavones. In the present study, among the four previously observed 
hydroxylated metabolites, only 7,8,4’-THI (8-hydroxydaidzein) was identified in rat 
plasma. The highest average of 7,8,4’-THI was measured at 5.1 μM in rat plasma 
within 30–60 min after intake of an average of 3.77 mg daidzin derivatives/kg BW. To 
the best of our knowledge, this is the first in vivo study that reports the bioavailability 
of hydroxylated metabolites of isoflavones at micro-molar concentrations in plasma 
after intake of soy isoflavone mixture. 
 The preventive bioactivity of 7,8,4’-THI on CVDs was then investigated using 
monocyte-endothelial adhesion assay. It has been reported that soybean-derived 
compounds have protective effect on overall atherosclerosis mechanism (Nagarajan, 
2010). It has been previously reported that soybean extract, soy isoflavone mixture, 
and genistein alone can inhibit monocyte-endothelial cell adhesion (Andrade, Sa & 
Toloi, 2012; Jia et al., 2013; Nagarajan, Stewart & Badger, 2006). However, 
hydroxylated metabolites of isoflavone including 7,8,4’-THI have not been studied for 
their atherosclerosis prevention activity. In the present study, we found that 7,8,4’-THI 
exerted stronger inhibitory effect on monocyte-endothelial adhesion compared to its 
precursor daidzein or daidzin. It was further demonstrated that 7,8,4’-THI could 
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attenuate protein and mRNA expression levels of atherosclerosis biomarkers such as 
VCAM-1 and MCP-1 stimulated by TNF-α. Additionally, 7,8,4’-THI suppressed the 
phosphorylation of IKK and IκBα in NF-κB signaling pathway. Therefore, 7,8,4’-THI 
appears to have significant impact for prevention of atherosclerosis. 
 
Conclusion 
 A few previous studies have found that 7,8,4’-THI has tyrosinase and 
melanogenesis inhibitory activities (Tai, Lin, Wu & Chang, 2009), anti-pruritic effects 
(Kim et al., 2014) and antioxidant activity against lipid peroxidation (Esaki, Onozaki, 
Morimitsu, Kawakishi & Osawa, 1998). However, this study is the first one that 
reports its anti-atherosclerotic effect. We demonstrated that 7,8,4’-THI rather than its 
native forms of isoflavones might be the one highly bioavailable in the circulating 
system and exerting CVD preventive bioactivity after soybean intake. However, the 
potential CVDs prevention effect of 7,8,4’-THI needs to be confirmed in vivo. In 
addition, target kinase of 7,8,4’-THI needs to be identified in order to elucidate its 
mechanisms involved in atherosclerosis prevention. 
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CHAPTER 5 
CONCLUSIONS 
  Soybean (Glycine max) has been recognized as an effective functional food 
that may prevent cardiovascular diseases (CVDs). Of the several soybean-derived 
bioactive components known, the claim that soy protein reduces the risk of 
cardiovascular heart disease (CHD) has been approved by the FDA. A meta-analysis 
has demonstrated that isoflavones can elicit additive or synergistic effects towards the 
CHD preventive effect of soy protein. In addition to soy protein and isoflavones, 
soybean (especially cultivars with black seed coats) contains additional phenolic 
compounds including proanthocyanidins and anthocyanins, which have also shown 
promising associations with CVD risk reduction. Our research has demonstrated that 
Yak-Kong (YK), a small black soybean cultivar with a green embryo, is a highly 
potent anti-atherosclerotic agent. This was determined by comparing its antioxidant 
activities with that of common yellow (YS) and black soybean (BS) cultivars, 
analyzing the representative phenolic groups in the seed coat and embryo, and 
investigating the preventive effects of the metabolites on monocyte-endothelial 
adhesion.  
 In the first study, we compared the total phenolic content, as well as flavonoid 
and anthocyanin content present in YK with that found in common YS and BS using 
colorimetric assays. Additionally, the antioxidant activity in the YK seed coat and 
embryo were separately compared with YS and BS, as antioxidant activity has been 
recognized as an important property that may counteract several risk factors of CVD 
and atherosclerosis. We identified a number of other representative phenolics in each 
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part of YK using UHPLC-MSMS, and determined that both the YK seed coat and 
embryo contain higher antioxidant activity and total phenolic content than YS and BS. 
In addition, comprehensive phenolic analysis results showed that YK is an excellent 
source of proanthocyanidins and isoflavones, which have previously been strongly 
associated with reductions in CVD risk factors. In particular, YK seed coat contains a 
broad phenolics profile that includes A-type procyanidin dimers, anthocyanins, 
protocatechuic acid and phloridzin, which have shown anti-atherosclerotic bioactivity 
in vivo.  
 The majority of previous studies on the biological properties of functional 
foods and their phenolic compounds have been conducted using their native forms. 
Although their potential preventive effects against several diseases have been 
demonstrated from in vitro cell models to in vivo clinical studies, the bioavailability of 
such compounds is often overlooked. Bioavailability is a critical factor for the 
development of functional foods, as it accounts for the actual concentrations that end 
up circulating in the human body and reaching the target organs and tissues. We 
sought to focus on the atherosclerosis preventive effects of metabolites derived from 
YK phenolics using a monocyte-endothelial cell adhesion assay which mimics the 
conditions of the first phase of atherosclerosis. 
 It has been previously reported that proanthocyanidins are subjected to 
microbial catabolism, which is strongly influenced by an individual’s gut microbiota 
profile. We therefore investigated major proanthocyanidin microbial metabolites that 
have been previously reported, and selected potential candidates that are likely to be 
bioavailable after ingestion of YK seed coat. Of the previously reported derivatives 
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including procyanidin A1, A2, B1 and B2, (epi)catechins, 5-(3’,4’-dihydroxyphenyl)-
γ-valerolactone (DHPV), 3-(3,4-dihydroxyphenyl)propionic acid and 2-(3,4-
dihydroxyphenyl)acetic acid, we determined that DHPV elicits the most potent 
preventive effect on monocyte-endothelial adhesion. 
 In the third study, the CVD preventive effect of isoflavone-rich YK embryo 
was investigated. Among the previously reported isoflavone metabolites, hydroxylated 
isoflavones have shown more potent antioxidant activity compared to their precursors. 
We then analyzed several major hydroxylated isoflavones and their precursors in the 
plasma of rats acutely supplemented with YK embryo extract. A daidzein metabolite, 
7,8,4’-trihydroxyisoflavone (7,8,4’-THI), was identified as being at the highest 
concentrations (average 5.1 μM) in rat plasma within 30–60 min after intake of an 
average of 3.77 mg daidzin derivative/kg per body weight of rat. Compared to its 
precursors daidzein and daidzin, 7,8,4’-THI showed a more potent preventive effect 
on TNF-α-stimulated monocyte-endothelial adhesion.  
 The mechanism responsible for the preventive bioactivity of DHPV and 7,8,4’-
THI on monocyte-endothelial adhesion was revealed to involve the downregulation of 
vascular cell adhesion molecule-1, monocyte chemotactic protein-1 and the 
phosphorylation of I Kappa B Kinase in the NF-κB signaling pathway, all of which 
are associated with atherosclerosis.  
 Taken together, our studies demonstrate that YK is an excellent source of soy 
protein, proanthocyanidins and isoflavones, and both seed coat and embryo together 
may contribute toward additional cardioprotective bioactivity. Notably, the major 
metabolites DHPV and 7,8,4’-THI have more favorable bioavailability profiles and 
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are therefore more likely to exert actual anti-atherosclerotic effects. 
